AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 337466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 7304486 — intervention group
Group type: EXPERIMENTAL
Intervention: Bengal gram dal (50 g carbohydrate)
Number of subjects: 6
Study 7304486 — intervention group
Group type: EXPERIMENTAL
Intervention: Rajmah (50 g carbohydrate)
Number of subjects: 6
Study 7304486 — intervention group
Group type: COMPARATOR
Intervention: Wheat (50 g carbohydrate)
Number of subjects: 6
Study 7304486 — intervention group
Group type: COMPARATOR
Intervention: Rice (50 g carbohydrate)
Number of subjects: 6
Study 7304486 — intervention group
Group type: COMPARATOR
Intervention: Dextrose (50 g carbohydrate)
Number of subjects: 6
Study 30979672 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific instrumentation (PSI)
Number of subjects: 69
Study 28699136 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrawound vancomycin
Number of subjects: 380
Study 28699136 — intervention group
Group type: COMPARATOR
Intervention: No intrawound vancomycin (Control)
Number of subjects: 380
Study 27431238 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2330672 for 14 days
Number of subjects: 0
Study 27431238 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2330672
Number of subjects: 0
Study 27431238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24401239 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day) + POMx (1g/day)
Number of subjects: 23
Study 24401239 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (20 mg/day) + placebo
Number of subjects: 23
Study 22677306 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium 25 mg liquid capsule
Number of subjects: 42
Study 22677306 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac potassium 2 x 12.5 mg tablets
Number of subjects: 42
Study 19730107 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium+FOS
Number of subjects: 125
Study 19730107 — intervention group
Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 125
Study 18584249 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride (15 mg by mouth with 50 ml of water three times a day starting on postoperative day 1)
Number of subjects: 40
Study 18584249 — intervention group
Group type: COMPARATOR
Intervention: Control (50 ml of water three times a day starting on postoperative day 1)
Number of subjects: 40
Study 15778565 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal meridian massage
Number of subjects: 31
Study 15778565 — intervention group
Group type: COMPARATOR
Intervention: No massage (Control)
Number of subjects: 31
Study 12204702 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost
Number of subjects: 532
Study 10496192 — intervention group
Group type: EXPERIMENTAL
Intervention: Vesnarinone 30 mg
Number of subjects: 0
Study 10496192 — intervention group
Group type: EXPERIMENTAL
Intervention: Vesnarinone 60 mg
Number of subjects: 0
Study 10496192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10496192 — intervention group
Group type: EXPERIMENTAL
Intervention: Vesnarinone (30 mg or 60 mg)
Number of subjects: 0
Study 8929752 — intervention group
Group type: EXPERIMENTAL
Intervention: ketamine 6.0 mg/kg j.i.
Number of subjects: 30
Study 8929752 — intervention group
Group type: EXPERIMENTAL
Intervention: ketamine 3.5 mg/kg j.i.
Number of subjects: 30
Study 8929752 — intervention group
Group type: EXPERIMENTAL
Intervention: ketamine 2.5 mg/kg j.i.
Number of subjects: 30
Study 8929752 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 1798280 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human superoxide dismutase (h‐SOD)
Number of subjects: 0
Study 1798280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6624506 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 50
Study 6624506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 29750571 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified 5-Year-Olds' Index
Number of subjects: 351
Study 29750571 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analogue scale (VAS)
Number of subjects: 351
Study 30400188 — intervention group
Group type: EXPERIMENTAL
Intervention: QADM composites (10% by mass of bis(2‐methacryloyloxyethyl) dimethylammonium bromide)
Number of subjects: 17
Study 30400188 — intervention group
Group type: COMPARATOR
Intervention: Control composite without QADM
Number of subjects: 17
Study 27492789 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg methylphenidate (MPH)
Number of subjects: 60
Study 27492789 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg propranolol (PRO)
Number of subjects: 60
Study 27492789 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 60
Study 24875077 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 60 mg 4 times a day
Number of subjects: 65
Study 24875077 — intervention group
Group type: COMPARATOR
Intervention: Placebo 4 times a day
Number of subjects: 65
Study 24875077 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.075 mg 4 times a day
Number of subjects: 65
Study 22538793 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial case management (comprehensive, individual advice about available treatment possibilities for dementia patients)
Number of subjects: 0
Study 22538793 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 0
Study 21030903 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 days of valganciclovir prophylaxis
Number of subjects: 318
Study 21030903 — intervention group
Group type: COMPARATOR
Intervention: 100 days of valganciclovir prophylaxis
Number of subjects: 318
Study 17259503 — intervention group
Group type: EXPERIMENTAL
Intervention: IFG6.1
Number of subjects: 1428
Study 17259503 — intervention group
Group type: EXPERIMENTAL
Intervention: IFG5.6
Number of subjects: 1428
Study 16142248 — intervention group
Group type: EXPERIMENTAL
Intervention: 123I-ioflupane radiopharmaceutical injected intravenously at a dose of 185 MBq
Number of subjects: 54
Study 16142248 — intervention group
Group type: COMPARATOR
Intervention: Normal volunteers (control group)
Number of subjects: 54
Study 16142248 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular imaging (SPET) with 123I-ioflupane
Number of subjects: 54
Study 16142248 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after eight months
Number of subjects: 54
Study 14571125 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous erosion and abrasion (toothbrushing with silica abrasive in citric acid)
Number of subjects: 0
Study 14571125 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating erosion and abrasion (brushing with silica abrasive after citric acid exposure)
Number of subjects: 0
Study 14571125 — intervention group
Group type: COMPARATOR
Intervention: Erosion alone (exposure to citric acid without brushing)
Number of subjects: 0
Study 14571125 — intervention group
Group type: COMPARATOR
Intervention: Brushing with silica abrasive after erosion
Number of subjects: 0
Study 14571125 — intervention group
Group type: COMPARATOR
Intervention: Brushing without abrasive after erosion
Number of subjects: 0
Study 10360450 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (100 ml 1 mmol/l)
Number of subjects: 12
Study 10360450 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (100 ml)
Number of subjects: 12
Study 8997938 — intervention group
Group type: EXPERIMENTAL
Intervention: Year-long nursing trial guided by the McGill Model of Nursing
Number of subjects: 0
Study 8997938 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement with the nurse
Number of subjects: 0
Study 8997938 — intervention group
Group type: EXPERIMENTAL
Intervention: Features of the nursing
Number of subjects: 0
Study 1786502 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory stimulation protocol
Number of subjects: 4
Study 1786502 — intervention group
Group type: COMPARATOR
Intervention: Pre-stimulation measures
Number of subjects: 4
Study 1786502 — intervention group
Group type: COMPARATOR
Intervention: Post-stimulation measures
Number of subjects: 4
Study 7353334 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 975 mg every 6 hr, started 22 hr before phenytoin dose and continued for 48 hr
Number of subjects: 6
Study 7353334 — intervention group
Group type: COMPARATOR
Intervention: Control group (phenytoin alone)
Number of subjects: 6
Study 7353334 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 975 mg every 6 hr
Number of subjects: 6
Study 29981804 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional bias modification training (attended to images of low-calorie food)
Number of subjects: 65
Study 29981804 — intervention group
Group type: COMPARATOR
Intervention: Control group (attended equally to images of high- and low-calorie food)
Number of subjects: 65
Study 27624608 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based parenting intervention (Triple P Online)
Number of subjects: 52
Study 27624608 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 52
Study 24385328 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypervolemic patients
Number of subjects: 60
Study 24385328 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid status (FO) and CNR
Number of subjects: 60
Study 22742885 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum Carbonate (LC)
Number of subjects: 1000
Study 20460548 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (80 mg/d)
Number of subjects: 42
Study 20460548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 19048025 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional dose 1/5 of the meningococcal polysaccharide vaccine
Number of subjects: 750
Study 19048025 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional dose 1/10 of the meningococcal polysaccharide vaccine
Number of subjects: 750
Study 19048025 — intervention group
Group type: COMPARATOR
Intervention: Full dose of the meningococcal polysaccharide vaccine
Number of subjects: 750
Study 19048025 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional doses (1/5 and 1/10) of the meningococcal polysaccharide vaccine
Number of subjects: 750
Study 19048025 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of the meningococcal polysaccharide vaccine
Number of subjects: 750
Study 15651055 — intervention group
Group type: EXPERIMENTAL
Intervention: Taking CHARGE intervention
Number of subjects: 25
Study 12464757 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose and nonnutritive sucking
Number of subjects: 190
Study 12464757 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose alone
Number of subjects: 190
Study 12464757 — intervention group
Group type: COMPARATOR
Intervention: Sterile water and nonnutritive sucking (control)
Number of subjects: 190
Study 10367299 — intervention group
Group type: EXPERIMENTAL
Intervention: Organized breast cancer screening
Number of subjects: 500
Study 10367299 — intervention group
Group type: COMPARATOR
Intervention: Personal invitation letter
Number of subjects: 500
Study 10367299 — intervention group
Group type: COMPARATOR
Intervention: Preliminary visit to the GP
Number of subjects: 500
Study 10367299 — intervention group
Group type: COMPARATOR
Intervention: Examination outside business hours
Number of subjects: 500
Study 8575589 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol administration of antipseudomonal antibiotics
Number of subjects: 12
Study 8575589 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nebulized solution)
Number of subjects: 12
Study 8575589 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol administration of antipseudomonal antibiotics as adjunct to intravenous therapy
Number of subjects: 12
Study 8575589 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol maintenance treatment with appropriate antibiotic in high enough dosage
Number of subjects: 12
Study 1781229 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal
Number of subjects: 99
Study 1781229 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 99
Study 6109855 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-weekly isoniazid, rifampicin, streptomycin, and ethambutol (without pyrazinamide)
Number of subjects: 971
Study 6109855 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-weekly isoniazid, rifampicin, streptomycin, and pyrazinamide
Number of subjects: 971
Study 6109855 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-weekly isoniazid, rifampicin, pyrazinamide, and ethambutol
Number of subjects: 971
Study 6109855 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-weekly isoniazid, rifampicin, pyrazinamide, and streptomycin
Number of subjects: 971
Study 6109855 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily isoniazid, rifampicin, pyrazinamide, and ethambutol
Number of subjects: 971
Study 31397120 — intervention group
Group type: COMPARATOR
Intervention: Intratracheal administration of corticosteroids (IAC)
Number of subjects: 1515
Study 28255756 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial coaching intervention (5 coaching sessions plus physiotherapy)
Number of subjects: 68
Study 28255756 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy alone (control group)
Number of subjects: 68
Study 25746670 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 or 60 weeks of combination antiretroviral therapy (cART)
Number of subjects: 47
Study 25746670 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 47
Study 23917585 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator (100 mg) or streptokinase (1,500,000 U)
Number of subjects: 168
Study 23917585 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfused group
Number of subjects: 168
Study 23917585 — intervention group
Group type: COMPARATOR
Intervention: Nonreperfused group
Number of subjects: 168
Study 21712241 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir-based regimen (immediate group)
Number of subjects: 170
Study 21712241 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir-based regimen (deferred group)
Number of subjects: 170
Study 21712241 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir and ritonavir‐boosted tipranavir
Number of subjects: 170
Study 21712241 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 170
Study 21712241 — intervention group
Group type: COMPARATOR
Intervention: Enfuvirtide-based regimen (maintenance arm)
Number of subjects: 170
Study 19187327 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg
Number of subjects: 16
Study 19187327 — intervention group
Group type: COMPARATOR
Intervention: Allergen challenge
Number of subjects: 16
Study 19187327 — intervention group
Group type: COMPARATOR
Intervention: AMP challenge
Number of subjects: 16
Study 19187327 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AMP and allergen challenges
Number of subjects: 16
Study 16682305 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter‐defibrillator (ICD) therapy
Number of subjects: 951
Study 16682305 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 951
Study 14745142 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nicorandil
Number of subjects: 0
Study 14745142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11215366 — intervention group
Group type: EXPERIMENTAL
Intervention: Human albumin (5-8 g/l ascites)
Number of subjects: 35
Study 11215366 — intervention group
Group type: COMPARATOR
Intervention: Reinfusion of ascitic-ultrafiltrate fluid by means of hemofiltration technique
Number of subjects: 35
Study 11215366 — intervention group
Group type: EXPERIMENTAL
Intervention: Human albumin
Number of subjects: 35
Study 11215366 — intervention group
Group type: COMPARATOR
Intervention: Reinfusion of ascitic-ultrafiltrate fluid
Number of subjects: 35
Study 11215366 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study 18476179 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin/Sulbactam (2 g/1 g, IV every 6 h)
Number of subjects: 93
Study 18476179 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (2 g, IV every 6 h)
Number of subjects: 93
Study 18476179 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin/Sulbactam
Number of subjects: 93
Study 18476179 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 93
Study 7792559 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (single dose)
Number of subjects: 551
Study 7792559 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime (thrice daily until the end of the second postoperative day)
Number of subjects: 551
Study 7792559 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime
Number of subjects: 551
Study 2509267 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 70 micrograms
Number of subjects: 10
Study 2509267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30362876 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical spinal stimulation
Number of subjects: 15
Study 30362876 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 15
Study 25910473 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone Auto-Injector (NAI)
Number of subjects: 42
Study 25910473 — intervention group
Group type: COMPARATOR
Intervention: Naloxone Intranasal Delivery System (NXN)
Number of subjects: 42
Study 23834117 — intervention group
Group type: EXPERIMENTAL
Intervention: NB‐UVB phototherapy
Number of subjects: 322
Study 23834117 — intervention group
Group type: COMPARATOR
Intervention: ETN 50 mg twice weekly
Number of subjects: 322
Study 23834117 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of NB‐UVB phototherapy and ETN
Number of subjects: 322
Study 21538218 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (pulsed infrared laser) and exercise therapy for ten sessions over 2 weeks
Number of subjects: 80
Study 21538218 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser and exercise therapy for ten sessions over 2 weeks
Number of subjects: 80
Study 18344556 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon
Number of subjects: 40
Study 18344556 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 40
Study 17162891 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrysof SA60AT IOL
Number of subjects: 117
Study 17162891 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecnis Z9001 IOL
Number of subjects: 117
Study 17162891 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensar AR40e IOL
Number of subjects: 117
Study 14592919 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MM)
Number of subjects: 0
Study 14592919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10750290 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder filled with 300 ml
Number of subjects: 20
Study 10750290 — intervention group
Group type: COMPARATOR
Intervention: Empty bladder
Number of subjects: 20
Study 10750290 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder filled with 200 ml
Number of subjects: 20
Study 8777274 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ng LPS/ml
Number of subjects: 0
Study 8777274 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 0
Study 8777274 — intervention group
Group type: EXPERIMENTAL
Intervention: High HDL
Number of subjects: 0
Study 8777274 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium doses of LPS (100 ng/ml)
Number of subjects: 0
Study 8777274 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of LPS (1 ng/ml)
Number of subjects: 0
Study 2050425 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g cefodizime
Number of subjects: 50
Study 2050425 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g cefodizime
Number of subjects: 50
Study 6342956 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sodium meclofenamate 3-times daily
Number of subjects: 40
Study 6342956 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg naproxen twice daily
Number of subjects: 40
Study 6342956 — intervention group
Group type: COMPARATOR
Intervention: Both treatment groups
Number of subjects: 40
Study 6342956 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium meclofenamate
Number of subjects: 40
Study 6342956 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen
Number of subjects: 40
Study 30528951 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet P high polyunsaturated (PUFAs) fat hypocaloric diet
Number of subjects: 362
Study 30528951 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet M high monounsaturated (MUFAs) fat hypocaloric diet
Number of subjects: 362
Study 30528951 — intervention group
Group type: COMPARATOR
Intervention: Control group (A allele carriers)
Number of subjects: 362
Study 27693237 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (3 sessions)
Number of subjects: 28
Study 27693237 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (5 sessions)
Number of subjects: 28
Study 27693237 — intervention group
Group type: COMPARATOR
Intervention: Placebo tDCS
Number of subjects: 28
Study 26520158 — intervention group
Group type: EXPERIMENTAL
Intervention: Reach Out and Read program (ROaR)
Number of subjects: 30
Study 26520158 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 30
Study 26466438 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorative resin-based composite with various polishing regimes
Number of subjects: 30
Study 26466438 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without diabetes mellitus)
Number of subjects: 30
Study 22829919 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly sulfadoxine-pyrimethamine (SP)
Number of subjects: 484
Study 22829919 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly sulfadoxine-pyrimethamine and two doses of azithromycin (AZI-SP)
Number of subjects: 484
Study 22829919 — intervention group
Group type: COMPARATOR
Intervention: Controls (sulfadoxine-pyrimethamine twice)
Number of subjects: 484
Study 22829919 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly sulfadoxine-pyrimethamine (SP) among HIV-negative participants
Number of subjects: 484